ArticleProstate cancer and prostatic diseases2022

Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study).

Daniel J George et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.